Top Banner Top Banner

1. American Cancer Society. Colorectal Cancer, 2011.

2. Giantonio BJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-1544.

3. Saltz LB, et al. Bevacizumab (BEV) in combination with XELOX or FOLFOX4: Updated efficacy results from XELOX-1/NO16966, a randomized phase III trial in first-line metastatic colorectal cancer. Proc ASCO 2007;25:18S.

4. Kozloff M, et al. Survival of patients with mCRC treated with bevacizumab in combination with chemotherapy: Results from the BRiTE registry. 2007 Gastrointestinal Cancers Symposium. A375.

5. Grothey A, et al. Association between exposure to bevacizumab (BEV) beyond first progression (BBP) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). Proc ASCO 2007 25:18S.

6. Saltz LB, et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan versus cetuximab/bevacizumab in irinotecan-refractory colorectal cancer. Proc ASCO 2005 23:16S.

7. System ENABLEā„¢.

Last updated March 1, 2012